Keros Therapeutics (NASDAQ: KROS) plans talks at Wells Fargo, Wainwright

Rhea-AI Filing Summary

Keros Therapeutics, Inc. filed a current report to share that its President and Chief Executive Officer, Jasbir Seehra, will speak at two upcoming investor conferences. On September 4, 2025, he is scheduled for a fireside chat at the 2025 Wells Fargo Healthcare Conference at 2:15 p.m. Eastern time. On September 9, 2025, he will give a corporate presentation at the H.C. Wainwright 27th Annual Global Investment Conference at 12:00 p.m. Eastern time.

The company disclosed this through a press release dated August 28, 2025, which is furnished as Exhibit 99.1. The information under this item is being treated as “furnished” rather than “filed” under the Exchange Act, which limits its use for certain legal liability purposes and incorporation into other securities filings unless specifically referenced.

0001664710FALSE00016647102025-08-282025-08-280001664710us-gaap:CommonStockMember2025-08-282025-08-280001664710us-gaap:PreferredStockMember2025-08-282025-08-28

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 28, 2025

Keros Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-39264

81-1173868

(state or other jurisdiction of incorporation)

(Commission File Number)

(I.R.S. Employer Identification No.)

1050 Waltham Street, Suite 302 Lexington, Massachusetts

02421

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (617) 314-6297

Not applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange on which registered

Common Stock, $0.0001 par value per share

KROS

The Nasdaq Stock Market LLC

Preferred Share Purchase Rights

N/A

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01     Regulation FD Disclosure.

On August 28, 2025, Keros Therapeutics, Inc. (the “Company”) issued a press release announcing that Jasbir Seehra, the Company’s President and Chief Executive Officer, will participate in a fireside chat presentation at the 2025 Wells Fargo Healthcare Conference on Thursday, September 4, 2025 at 2:15 p.m. Eastern time, and a corporate presentation at the H.C. Wainwright 27th Annual Global Investment Conference on Tuesday, September 9, 2025 at 12:00 p.m. Eastern time. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibit is not incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.

Item 9.01     Financial Statements and Exhibits.

(d) Exhibits

Exhibit
No.						Description
99.1						Press Release dated August 28, 2025.
104						Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

KEROS THERAPEUTICS, INC.
By:						/s/ Jasbir Seehra
						Jasbir Seehra, Ph.D. Chief Executive Officer

Dated: August 28, 2025

FAQ

What did Keros Therapeutics (KROS) disclose in this 8-K?

Keros Therapeutics disclosed that CEO Jasbir Seehra will participate in a fireside chat at the 2025 Wells Fargo Healthcare Conference and present at the H.C. Wainwright 27th Annual Global Investment Conference, as detailed in a press release furnished as Exhibit 99.1.

When will Keros Therapeutics’ CEO present at the Wells Fargo Healthcare Conference?

CEO Jasbir Seehra is scheduled for a fireside chat at the 2025 Wells Fargo Healthcare Conference on Thursday, September 4, 2025 at 2:15 p.m. Eastern time.

When is Keros Therapeutics presenting at the H.C. Wainwright Global Investment Conference?

Keros Therapeutics will deliver a corporate presentation at the H.C. Wainwright 27th Annual Global Investment Conference on Tuesday, September 9, 2025 at 12:00 p.m. Eastern time.

How is the information in this KROS 8-K treated under SEC rules?

The information about the conference appearances, including Exhibit 99.1, is being furnished under Regulation FD and is not deemed “filed” for purposes of Section 18 of the Exchange Act, nor incorporated into other securities filings unless specifically referenced.

What exhibits are attached to this Keros Therapeutics 8-K filing?

The filing includes Exhibit 99.1, a press release dated August 28, 2025, and Exhibit 104, the cover page interactive data file with embedded Inline XBRL tags.